Research
Hormonal
Several factors, including KLF2, GATA2/3, Pref-1, TAZ, and SIRT1, negatively regulate adipogenesis by inhibiting PPARγ and C/EBPα expression, thereby preventing the formation of mature adipocytes.
The body has natural 'brakes' on fat cell formation (like Pref-1 and SIRT1). Understanding these can lead to therapies that enhance these brakes to prevent obesity.
GoodRefutesHIGH confidence
Bodies of scientific knowledge indicate that several factors are capable of inhibiting adipogenic differentiation... KLF2 inhibits adipogenic differentiation... GATA2 and GATA3 inhibit adipogenesis... Pref-1 expression inhibits adipocyte differentiation... TAZ... suppresses adipocyte differentiation... SIRT1 plays a negative role during adipogenic differentiation
Why this rating
Supported by multiple in vitro and in vivo studies across different cell lines and animal models.
Source
Molecular Regulation of Adipogenesis and Potential Anti-Adipogenic Bioactive Molecules
Dorothy Moseti et al. · International Journal of Molecular Sciences · 2016
DOI 10.3390/ijms17010124
narrative_reviewCited 749×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- PPARγ is the master regulator of adipogenesis; its presence is necessary and sufficient for the differentiation of precursor cells into mature adipocytes, whereas its absence prevents fat cell formation.Strong
- PPARγ2, but not PPARγ1, plays the key role in adipogenic differentiation, as evidenced by the failure of cells with reduced PPARγ2 to differentiate and the inability of PPARγ1 to restore it.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →